Biosimilar copies of blockbuster drug launch in major EU markets

February 25, 2015 8:32 AM

16 0

LONDON (Reuters) - Cheap versions of a top-selling drug for rheumatoid arthritis and Crohn's disease are being launched across major European markets in an important advance for a new type of medicines known as biosimilars.

The products from South Korean firm Celltrion and its partners Hospira and Mundipharma will compete with Remicade, the original branded drug from Johnson & Johnson and Merck & Co.

Read more

To category page